Absci
Absci is a biotechnology company leveraging generative AI for drug discovery, creating innovative therapeutics through an integrated platform that combines AI models with synthetic biology data. The company is committed to advancing personalized medicine and rapid biologics development.
Headquarters
Vancouver, Washington, United States
Company Size
51-200 employees
Founded
2011
Absci is a clinical-stage biopharmaceutical company that applies generative AI, synthetic biology, and cell‑line engineering to accelerate discovery and development of biologic therapeutics. Its proprietary platform combines machine learning–driven protein design with high‑throughput lab workflows and engineered cell lines to generate and optimize expressible, developable candidates more quickly. Absci advances its own clinical programs and collaborates with biopharma partners to discover and progress novel protein and antibody-based medicines. Companies work with Absci for an AI‑driven, end‑to‑end discovery engine that shortens timelines and de‑risks biologics development.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Absci.
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage
4 days ago
Director – Protein Therapeutics
Gilead Sciences
All
Synolo Therapeutics
Scientist II, Antibody Engineering
Astellas
Sr Scientist -- Biologics Engineering, Protein Therapeutics
Gilead Sciences
Advisor - Protein Engineering and CAR Design
Eli Lilly and Company
Principal Scientist to Director, Structural Biology
Structure Therapeutics